Literature DB >> 31227476

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.

Elisavet Chartomatsidou1,2, Stavroula Ntoufa1, Konstantia Kotta1, Alessandra Rovida3, Maria Anna Akritidou1,2, Daniela Belloni3, Elisabetta Ferrero3, Theoni Trangas2, Niki Stavroyianni4, Achilles Anagnostopoulos4, Richard Rosenquist5,6, Paolo Ghia3, Nikos Papakonstantinou1, Kostas Stamatopoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31227476      PMCID： PMC6595263          DOI： 10.1182/bloodadvances.2018030262

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

Review 1.  The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Semin Cancer Biol       Date:  2015-05-09       Impact factor: 15.707

2.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

3.  Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Authors:  Stavroula Ntoufa; Anna Vardi; Nikos Papakonstantinou; Achilles Anagnostopoulos; Vassiliki Aleporou-Marinou; Chrysoula Belessi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

4.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps
Journal:  Blood       Date:  2018-03-14       Impact factor: 22.113

5.  Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.

Authors:  Doralina do Amaral Rabello; Antonio Roberto Lucena-Araujo; Juliana Carvalho Rocha Alves-Silva; Vinícius Burnett Aboud Souza da Eira; Maria Catarina Cals de Vasconcellos; Fábio Morato de Oliveira; Eduardo Magalhaes Rego; Felipe Saldanha-Araujo; Fábio Pittella Silva
Journal:  Blood Cells Mol Dis       Date:  2014-08-15       Impact factor: 3.039

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 7.  Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.

Authors:  Ayed O Ayed; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2017-11-08

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 9.  Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.

Authors:  Ludovica Morera; Michael Lübbert; Manfred Jung
Journal:  Clin Epigenetics       Date:  2016-05-24       Impact factor: 6.551

10.  The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

Authors:  Nikos Papakonstantinou; Stavroula Ntoufa; Elisavet Chartomatsidou; Konstantia Kotta; Andreas Agathangelidis; Lefki Giassafaki; Tzeni Karamanli; Panagiota Bele; Theodoros Moysiadis; Panagiotis Baliakas; Lesley Ann Sutton; Niki Stavroyianni; Achilles Anagnostopoulos; Antonios M Makris; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Oncotarget       Date:  2016-06-14
View more
  3 in total

1.  Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.

Authors:  Martin Böttcher; Heiko Bruns; Simon Völkl; Junyan Lu; Elisavet Chartomatsidou; Nikos Papakonstantinou; Kristin Mentz; Maike Büttner-Herold; Thorsten Zenz; Marco Herling; Wolfgang Huber; Paolo Ghia; Kostas Stamatopoulos; Andreas Mackensen; Dimitrios Mougiakakos
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 2.  Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape.

Authors:  Laia Sadeghi; Anthony P Wright
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 3.  Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.

Authors:  Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Biomark Res       Date:  2020-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.